DiNuzzo Private Wealth
DNLI icon

DiNuzzo Private Wealth’s Denali Therapeutics DNLI Stock Holding History

DiNuzzo Private Wealth’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$249 Buy
12
+2
+20% +$47 ﹤0.01% 1244
2026
Q2 		$258 Buy
10
+8
+400% +$164 ﹤0.01% 1223
2026
Q1 		$39 Buy
+2
New +$40 ﹤0.01% 1319
2025
Q2 		– Sell
-2
Closed -$28 – 1375
2025
Q1 		$28 Buy
+2
New +$38 ﹤0.01% 1355

Other funds holding DNLI

Temasek Holdings
Temasek Holdings Singapore $36.7B AUM 6.83% 1-Year Est. Return
E. Ohman J:or Asset Management
E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Yorktown Management & Research Company
Yorktown Management & Research Company Forest, Virginia $150M AUM 39.02% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
J. Safra Sarasin Holding
J. Safra Sarasin Holding $7.05B AUM 26.14% 1-Year Est. Return
B. Riley Wealth Advisors
B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return

DiNuzzo Private Wealth's DNLI Position: Q3 2026 in Review

DiNuzzo Private Wealth increased its Denali Therapeutics (DNLI) stake by 20% in Q3 2026, buying an estimated $47 and bringing the position to 12 shares worth $249. The position accounts for ﹤0.01% of the portfolio, ranked #1244.

DiNuzzo Private Wealth first reported a position in DNLI in Q1 2025 and has held it in 4 quarters since. The position peaked at $258 in Q2 2026. 54 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • DiNuzzo Private Wealth held 12 shares of Denali Therapeutics worth $249 as of Q3 2026.
  • DiNuzzo Private Wealth bought 2 Denali Therapeutics shares in Q3 2026, an estimated $47.
  • Denali Therapeutics made up ﹤0.01% of DiNuzzo Private Wealth's portfolio in Q3 2026, its #1244 holding.
  • DiNuzzo Private Wealth first reported a position in Denali Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • DiNuzzo Private Wealth's Denali Therapeutics position peaked at $258 in Q2 2026.
  • 54 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on DiNuzzo Private Wealth's 13F filing for Q3 2026, filed 16 Oct 2026.